Ortho Clinical Diagnostics Holdings PLC
NASDAQ:OCDX
Ortho Clinical Diagnostics Holdings PLC
NASDAQ:OCDX
Price:
17.63 USD
0.46%
Market Closed
Updated:
May 15, 2024
P/FCFE
Price to FCFE
Price to FCFE
43
Current
-87.8
Median
22.5
Industry
Higher
than median
Higher
than industry value
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
P/FCFE
=43
Market Cap
/
4.2B
FCFE
97.4m
All Countries
| Market Cap | P/FCFE | ||||
|---|---|---|---|---|---|
| US |
|
Ortho Clinical Diagnostics Holdings PLC
NASDAQ:OCDX
|
4.2B USD | 43 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
180.9B USD | 76.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
136.3B USD | 228.7 | |
| US |
|
Stryker Corp
NYSE:SYK
|
123.5B USD | 46.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
112.1B USD | 80.6 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
108B USD | 32.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
67.9B USD | 32.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
59.2B EUR | 69.5 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
378.5B CNY | 37.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
52B USD | 85.1 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
49.9B USD | 85.5 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A
You don't have any saved screeners yet
